Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
about
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's diseaseCurrent Research Therapeutic Strategies for Alzheimer's Disease TreatmentTyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsPharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disordersMasitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression.ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.Mast cells and neuroinflammation.Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance.Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient.Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis.Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosisInhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules.Fyn kinase inhibition as a novel therapy for Alzheimer's disease.Mast cells: an expanding pathophysiological role from allergy to other disorders.Successes and failures for drugs in late-stage development for Alzheimer's diseaseLatest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.Masitinib for the treatment of mild to moderate Alzheimer's disease.Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?Targeting Fyn Kinase in Alzheimer's Disease.Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.Epileptic activity in Alzheimer's disease: causes and clinical relevance.Neuroprotective effect of masitinib in rats with postischemic stroke.Memantine for the Treatment of Dementia: A Review on its Current and Future Applications.Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS.Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.An Inflammation-Centric View of Neurological Disease: Beyond the Neuron.Emerging Roles of Immune Cells in Postoperative Cognitive Dysfunction.
P2860
Q21146622-7A24BA8D-8400-4D3E-A048-20FB8CCBB7EFQ26765530-2CEA39B2-13A2-4C5C-86C9-A9137E4D527EQ28078946-9866832F-8BCD-495C-B779-3CAC64D5E487Q29048615-73BCABBD-77AE-41EE-9A2B-05BCF83A1103Q34301521-EDD9A65C-872C-4E04-B02D-20AB43AF5E2EQ34321423-A837A38A-0FF9-4B4F-8256-88D32F6138A9Q34554820-01802F5A-CF35-4D51-97AA-D5BF2B159426Q34677487-08AC9F99-BA4C-49C3-A7E3-2AE3CD8820F2Q34810678-60915475-A022-4234-B83D-AAE6ABD95771Q35542753-D5E45898-731C-4E3C-8F92-B3920D5F9AE4Q36085618-4D5C517D-1857-4EFC-BA14-4AAECB870362Q36955447-81250974-1E65-49E3-BCDF-382376C579D1Q37085041-20425406-1E62-4CD1-A4C3-7D0B936CD197Q37417421-F81167A5-B81A-489B-A275-9EE271960DFFQ37689640-3B3F95F4-37BC-40AE-81BD-4F2BF6E9A054Q38007884-7CBEF780-ED78-4F69-B035-7809FADE4E2DQ38128773-1027CE60-6005-4AF7-BE54-FDEE4A4DEA27Q38225930-B673D0D1-42CF-4FA4-A798-7A11E01AD879Q38472067-9349D6A8-8C2F-4CE7-B7C9-77B3EDA111D0Q38553317-034584EC-63AB-41DB-BD3D-7B48FB85BEC1Q38678555-E26C1240-24FB-4ECF-A95C-8B07FFA5202CQ39022532-57B31CCA-132C-4B51-B323-FD60E8571377Q39192571-96B18B3F-8C89-4B5D-889F-DCE9EE74E601Q43091544-6C083B7A-7E89-414C-B23D-1B0079149AA2Q47280369-ABE10E69-4076-48E9-91F5-7BBEE3B98709Q47860695-6EC659DC-A008-4EA0-B7C1-691ED42F2F45Q50091408-307B3A61-BFD1-418C-96DD-9FE1692AD372Q52316247-D9EA8240-E27F-435D-8AA0-70A32278101CQ52331711-2162D76A-D810-42E6-8BD1-DE53B302DFDCQ55020535-680BEAC6-DE67-4E22-8FF9-DE152E0C17FE
P2860
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Masitinib as an adjunct therap ...... cebo-controlled phase 2 trial.
@ast
Masitinib as an adjunct therap ...... cebo-controlled phase 2 trial.
@en
type
label
Masitinib as an adjunct therap ...... cebo-controlled phase 2 trial.
@ast
Masitinib as an adjunct therap ...... cebo-controlled phase 2 trial.
@en
prefLabel
Masitinib as an adjunct therap ...... cebo-controlled phase 2 trial.
@ast
Masitinib as an adjunct therap ...... cebo-controlled phase 2 trial.
@en
P2093
P2860
P50
P921
P356
P1476
Masitinib as an adjunct therap ...... cebo-controlled phase 2 trial.
@en
P2093
Alain Moussy
Caroline Marquis
François Piette
Hélène Vincent
Jean-Pierre Kinet
Joël Belmin
Laurence Hugonot-Diener
Nicolas Schmidt
Sylvie Pariel
P2860
P2888
P356
10.1186/ALZRT75
P407
P577
2011-04-19T00:00:00Z
P5875
P6179
1049566377